Articles tagged "Adverse effects"

2021 American Transplant Congress
Predictors of Postoperative Atrial Fibrillation in an Urban, Obese Adult Renal Transplant Population
A. Lichvar, Z. Ress, M. Tabriz, H. Jenkins, T. Walsh, I. Tzvetanov, E. Benedetti, M. Campara
University of Illinois at Chicago, Chicago, IL
*Purpose: Postoperative atrial fibrillation (POAF) is a common surgical complication. Renal transplant (RT) recipients possess risk factors that may lead to a higher incidence of…
2021 American Transplant Congress
Tolerability of De Novo and Conversion Belatacept Regimens in Kidney Transplantation
T. Le¹, J. Shoji², J. Phillips¹, D. Quan¹
¹Pharmaceutical Services, UCSF Medical Center, San Francisco, CA, ²Transplant Nephrology, UCSF Medical Center, San Francisco, CA
*Purpose: Belatacept, a selective T lymphocyte co-stimulation blocker, has been shown to be a safe and effective maintenance therapy for immunosuppression. We investigated the long-term…
2021 American Transplant Congress
Outcomes of Granulocyte-Colony Stimulating Factor Use in Pediatric Renal Transplant Recipients: A Pediatric Nephrology Research Consortium Study
R. M. Engen¹, P. L. Weng², W. Shih³, H. Patel⁴, K. Richardson⁵, S. Dowdrick⁶, I. Ashoor⁷, J. Misurac⁸, A. Z. Traum⁹, M. Semanik¹⁰, N. G. Jain¹¹, R. Sreedharan¹²
¹Northwestern University, Chicago, IL, ²University of California Los Angeles, Los Angeles, CA, ³University of Michigan, Ann Arbor, MI, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵Oregon Health & Science University, Portland, OR, ⁶Penn State Health, Hershey, PA, ⁷Louisiana State University, New Orleans, LA, ⁸University of Iowa, Iowa City, IA, ⁹Harvard University, Boston, MA, ¹⁰University of Wisconsin-Madison, Madison, WI, ¹¹Columbia University, New York, NY, ¹²Medical College of Wisconsin, Milwaukee, WI
*Purpose: Neutropenia is common after pediatric kidney transplant and is associated with an increased risk of bacterial infection, allograft loss, and death. Granulocyte colony-stimulating factor…
2021 American Transplant Congress
Non-Alcoholic Fatty Liver Disease in Non-Liver Transplant Patients
R. Claudio¹, C. Conceicao², K. Robichaux², A. Kumar¹, J. Buggs³, N. Kemmer⁴
¹Morsani College of Medicine, University of South Florida, Tampa, FL, ²Honors College, University of South Florida, Tampa, FL, ³Transplant Surgery, Tampa General Hospital, Tampa, FL, ⁴Transplant Hepatology, Tampa General Hospital, Tampa, FL
*Purpose: The global prevalence of non-alcoholic fatty liver disease (NAFLD) is rising at an alarming rate, driven in large part by an increased incidence of…
2021 American Transplant Congress
Evaluation of the Conversion from Tacrolimus to Sirolimus in Liver Transplant Recipients
H. Bakhtiari¹, S. Todd², H. Snyder², D. Lo², M. Flynn²
¹Mercer University College of Pharmacy, Atlanta, GA, ²Emory University Hospital, Atlanta, GA
*Purpose: The purpose of this study was to compare outcomes in liver transplant patients maintained on standard calcineurin inhibitor (CNI) therapy with tacrolimus versus those…
2021 American Transplant Congress
The Initial Impact of Covid-19 on Reported Graft Failure Rates and Potential Confounding of Srtr Psrs
A. Wey¹, J. Miller¹, D. Musgrove¹, Y. Ahn¹, M. Valapour², N. Salkowski¹, M. Skeans¹, A. Massie³, R. Hirose⁴, D. Segev³, A. Israni¹, J. Snyder¹, B. Kasiske¹
¹SRTR, Minneapolis, MN, ²Cleveland Clinic, Cleveland, OH, ³Johns Hopkins, Baltimore, MD, ⁴Univ of California, San Francisco, San Francisco, CA
*Purpose: COVID-19 could bias the Scientific Registry of Transplant Recipients (SRTR) program-specific reports (PSRs), especially if its impact varied geographically.*Methods: Recipients who received transplants from…
2021 American Transplant Congress
Varicella Hepatitis Mimicking Immune Checkpoint Inhibitor-induced Liver Toxicity
M. J. Weiss¹, X. Zhang², E. K. Spengler¹
¹Gastroenterology and Hepatology, University of Wisconsin, Madison, WI, ²Pathology, University of Wisconsin, Madison, WI
*Purpose: Nivolumab is an anti-PD-1 monoclonal antibody belonging to a class of immune checkpoint inhibitors (ICI) used for many malignancies. A major limitation to their…
2021 American Transplant Congress
The Effect of Covid-19 on Offer Acceptance Rates by Age and Race Groups
A. Wey¹, J. Miller¹, Y. Ahn¹, D. Musgrove¹, A. Hart¹, N. Salkowski¹, M. Skeans¹, R. Hirose², A. Israni¹, J. Snyder¹, B. Kasiske¹
¹SRTR, Minneapolis, MN, ²Univ of San Fransico, San Francisco, CA
*Purpose: COVID-19 causes more severe complications in older patients and disproportionately leads to poor outcomes in racial minorities. High offer acceptance rates indicate better access…
2021 American Transplant Congress
Post Pediatric Liver Transplant Immunosuppression: What’s the Caregivers’ Perspective?
I. D. Batsis¹, J. C. Bucuvalas¹, E. Eisenberg², J. Lau², S. Feng³, E. Perito⁴
¹Pediatric Hepatology, Mount Sinai Hospital, NY, New York, NY, ²Patient and Family Engaged Partners, SPLIT, New York, NY, ³Pediatric Transplant Surgery, UCSF, San Francisco, CA, ⁴Pediatric Hepatology, UCSF, San Francisco, CA
*Purpose: For children with liver transplants (LT), achieving an “ideal outcome” is a balancing act: too little immunosuppression (IS) begets graft injury; too much IS…
2021 American Transplant Congress
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
Z. A. Yetmar¹, E. Beam¹, J. C. O'Horo¹, R. Ganesh², D. M. Bierle², L. Brumble³, M. T. Seville⁴, R. R. Razonable¹
¹Infectious Diseases, Mayo Clinic, Rochester, MN, ²General Internal Medicine, Mayo Clinic, Rochester, MN, ³Infectious Diseases, Mayo Clinic, Jacksonville, FL, ⁴Infectious Diseases, Mayo Clinic, Scottsdale, AZ
*Purpose: Bamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild-to-moderate COVID-19 in patients at high-risk for progression to severe disease or hospitalization. For…